One of the new drugs that are in clinical development for IBD, but already approved for the treatment of rheumatoid arthritis, is Baricitinib, a selective Janus kinase (JAK1, JAK2) and AP2-associated protein kinase 1 (AAK1) inhibitor. Here, JAK2 is linked to inflammatory bowel disease.